Rezdiffra (Resmetirom): How It Works, How to Take It, and What the Clinical Data Show

Does Resmetirom Require Self-Injection?

Resmetirom does not require any injection. Rezdiffra is an oral solid tablet swallowed once daily with food. Patients who have read about GLP-1 receptor agonists or peptide therapies sometimes expect a subcutaneous injection, but resmetirom's route of administration is entirely different.

The FDA prescribing label for Rezdiffra specifies oral administration at either 80 mg or 100 mg once daily, dose-selected by the prescribing physician based on tolerability and response. The FDA approval page and prescribing information are available at the FDA drug database.

Why an Oral Drug for a Liver Disease?

Resmetirom reaches the liver at therapeutically relevant concentrations because it is preferentially taken up by hepatocytes via organic anion transporting polypeptides (OATPs). This hepatic first-pass enrichment means systemic thyroid hormone receptor activation stays low, limiting cardiovascular and bone side effects that limited earlier, non-selective thyroid hormone analogues. OATP-mediated hepatic uptake of resmetirom was characterized in preclinical pharmacokinetic studies published in Drug Metabolism and Disposition.

How to Take Rezdiffra Correctly

Take the tablet at the same time each day with a meal. If a dose is missed and more than 12 hours remain before the next scheduled dose, take it as soon as remembered. If fewer than 12 hours remain, skip the missed dose and resume the regular schedule. Do not crush or split the tablet; the solid formulation supports consistent absorption. Full prescribing information for Rezdiffra is indexed at accessdata.fda.gov.

How Resmetirom Works: The THR-β Mechanism

Resmetirom is a selective thyroid hormone receptor beta agonist. THR-β is the dominant thyroid receptor isoform expressed in the liver, and it governs hepatic lipid metabolism, mitochondrial biogenesis, and bile acid synthesis. By binding THR-β with high selectivity over THR-α (the cardiac and bone isoform), resmetirom shifts liver metabolism toward fatty acid oxidation without the tachycardia or bone-density losses associated with systemic hyperthyroidism. A detailed receptor pharmacology review is available via PubMed.

Reducing Hepatic Fat

Activated THR-β increases the transcription of genes that drive mitochondrial beta-oxidation of fatty acids inside hepatocytes. At the same time, it suppresses lipogenic pathways by downregulating SREBP-1c target genes. The combined effect is a measurable reduction in liver fat fraction within weeks of starting treatment. In MAESTRO-NASH, magnetic resonance imaging proton density fat fraction (MRI-PDFF) dropped by roughly 38% from baseline in patients on the 100 mg dose at week 52, compared with approximately 9% in the placebo group. MAESTRO-NASH full data: NEJM 2024.

Improving Liver Histology

Reducing intrahepatic lipid load lowers the substrate for lipid peroxidation, one of the primary triggers of hepatic stellate cell activation and fibrosis progression. This mechanistic chain translates to histological benefit. In MAESTRO-NASH (N=966), 29.9% of patients on resmetirom 100 mg achieved NASH resolution without worsening fibrosis at week 52, versus 9.7% on placebo (P<0.001). Fibrosis improvement of at least one stage was seen in 25.9% of the 100 mg group versus 14.2% of the placebo group (P<0.001). MAESTRO-NASH primary endpoint data: NEJM 2024.

Lowering Atherogenic Lipids

THR-β activation in hepatocytes also upregulates LDL receptors and increases conversion of cholesterol to bile acids, producing meaningful reductions in LDL-C, apolipoprotein B, and triglycerides. In MAESTRO-NASH, LDL cholesterol fell by approximately 16% in the 100 mg arm versus a 3% reduction in the placebo arm at 52 weeks. This lipid-lowering effect may matter clinically because MASH carries elevated cardiovascular risk independent of traditional lipid panels. Cardiovascular risk in NAFLD/MASH is reviewed at PubMed.

The MAESTRO-NASH Trial: Key Numbers Every Patient Should Know

MAESTRO-NASH was the phase 3 key trial that supported FDA approval of resmetirom. The trial enrolled 966 adults with biopsy-confirmed MASH and fibrosis stage F1B through F3, randomized 1:1:1 to resmetirom 80 mg, resmetirom 100 mg, or placebo for 52 weeks. Full trial registration and protocol: ClinicalTrials.gov NCT03900429.

Primary Endpoints

Two co-primary endpoints were specified:

1. NASH resolution (NAS score reduction of ≥2 points with no worsening fibrosis)
2. Fibrosis improvement of ≥1 stage without worsening of NASH activity score

Both endpoints were met at both doses. The 80 mg arm showed NASH resolution in 25.9% of patients vs. 9.7% placebo, and fibrosis improvement in 24.2% vs. 14.2% placebo. The 100 mg arm produced NASH resolution in 29.9% and fibrosis improvement in 25.9%. All comparisons reached P<0.001. NEJM 2024 primary publication.

Secondary Lipid and Metabolic Outcomes

At week 52, the 100 mg group showed a 16.3% reduction in LDL-C, a 19.7% reduction in apolipoprotein B, and a 22.7% reduction in triglycerides relative to placebo-adjusted changes. These are clinically meaningful shifts in a population already at elevated cardiometabolic risk. Lipid secondary endpoints reported in NEJM 2024.

Trial Population Characteristics

The median body mass index of enrolled patients was approximately 35 kg/m². About 58% had type 2 diabetes. Roughly 67% had F2 fibrosis and 33% had F3 fibrosis. This population reflects the real-world MASH patient seen in hepatology and endocrinology practices. MAESTRO-NASH baseline characteristics: NEJM 2024.

Who Qualifies for Resmetirom

The FDA label restricts Rezdiffra to adults with MASH and moderate-to-advanced fibrosis (F2 or F3 on liver biopsy). Patients with compensated or decompensated cirrhosis (F4) were excluded from MAESTRO-NASH, so evidence is limited in that population.

Diagnostic Requirements

A liver biopsy confirming MASH histology and fibrosis stage is required before initiating resmetirom. Non-invasive tests such as FibroScan or MRI elastography can support clinical decision-making but do not substitute for biopsy in the current label context. AASLD practice guidance on NAFLD/NASH diagnosis is available via PubMed.

Contraindications and Cautions

Resmetirom is contraindicated in pregnancy. Women of reproductive potential should use effective contraception during treatment. Patients with severe renal impairment (eGFR <15 mL/min/1.73 m²) were not studied. Drug interactions are a concern with OATP inhibitors (cyclosporine, rifampin) and strong CYP2C8 inhibitors; dose adjustment may be required. FDA prescribing information for drug interactions.

Dosing Protocol: Starting and Adjusting Resmetirom

The standard starting dose is 80 mg once daily with food for the first four weeks. At week four, if the drug is well tolerated, clinicians may increase to 100 mg once daily. Patients with body weight below 40 kg should remain on 80 mg. Patients on concomitant OATP1B inhibitors should also remain on 80 mg.

Monitoring After Starting Treatment

• Liver enzymes (ALT, AST): Check at baseline, week 4, week 12, and every 12 weeks thereafter.
• Lipid panel: Check at baseline and periodically during treatment; resmetirom reduces LDL-C and may affect statin dosing needs.
• Thyroid function: TSH should be checked at baseline. Resmetirom does not typically suppress TSH at therapeutic doses due to hepatic selectivity, but monitoring is prudent.
• Pregnancy test: Confirm negative status before initiation in women of childbearing potential.

FDA full prescribing information outlines monitoring parameters in detail.

Dose Reduction or Discontinuation

If ALT rises above 3 times the upper limit of normal and is confirmed on repeat testing, the dose should be reduced from 100 mg to 80 mg or discontinued depending on clinical context. If ALT exceeds 10 times the upper limit of normal, resmetirom should be stopped immediately. Symptomatic liver injury with jaundice warrants permanent discontinuation. Hepatotoxicity monitoring guidance: FDA prescribing label.

Side Effects: What Patients Experience

The most common adverse effects in MAESTRO-NASH were gastrointestinal and were more frequent during the first four to eight weeks of treatment. Nausea occurred in 26% of the 100 mg group vs. 11% placebo. Diarrhea was reported in 28% vs. 14%. Most cases were mild-to-moderate, and discontinuation due to gastrointestinal adverse events was low (approximately 2%). MAESTRO-NASH safety data: NEJM 2024.

Managing Gastrointestinal Symptoms

Taking the tablet with a larger meal reduces nausea for most patients. Splitting the dose is not recommended because the tablet is formulated for once-daily dosing. Temporary dose reduction from 100 mg back to 80 mg is an option if gastrointestinal symptoms persist beyond four weeks at the higher dose. FDA prescribing information for adverse reaction management.

Gallbladder Effects

Thyroid hormone receptor beta activation increases bile acid synthesis, which may alter bile composition and raise the risk of cholelithiasis. In MAESTRO-NASH, gallstone-related adverse events occurred in approximately 8% of resmetirom patients versus 4% in the placebo arm. Patients with prior cholecystectomy are not at added risk for this complication. Bile acid metabolism and THR-β: PubMed review.

Cardiac and Bone Safety

Because resmetirom spares THR-α, heart rate and bone mineral density remain stable at therapeutic doses. In MAESTRO-NASH, there was no statistically significant difference in major adverse cardiovascular events between groups. This stands in contrast to older non-selective thyroid hormone analogues such as diiodothyropropionic acid (DITPA), which caused tachycardia and other cardiac effects in clinical testing. THR selectivity and cardiac safety: PubMed.

How Resmetirom Fits Into the MASH Treatment Picture

Lifestyle modification, including a caloric deficit and at least 150 minutes of moderate physical activity per week, remains the foundation of MASH management per AASLD guidelines. Resmetirom adds a pharmacological layer for patients who have documented F2 or F3 fibrosis and have not achieved sufficient histological response through lifestyle changes alone. AASLD guidance on MASH management: PubMed.

Combination With GLP-1 Receptor Agonists

GLP-1 receptor agonists such as semaglutide reduce liver fat primarily through weight loss and improved insulin sensitivity. Resmetirom acts directly at the hepatocyte level via THR-β, a different pathway. Early mechanistic rationale supports potential additive benefit, though no randomized head-to-head or combination trial in MASH has yet reported outcomes. Clinicians are beginning to use both in selected patients with coexisting obesity and type 2 diabetes, pending more data. GLP-1 effects on NAFLD: PubMed review.

Role of Vitamin E and Pioglitazone

Vitamin E (800 IU daily) and pioglitazone (30 to 45 mg daily) have prior AASLD guideline support for specific MASH subgroups. Neither has an FDA approval for MASH with fibrosis. Resmetirom now holds that approval and is the preferred pharmacological option when the label criteria are met. AASLD NAFLD/NASH practice guidance: PubMed.

Guideline Context and Clinical Expert Perspectives

The AASLD 2023 practice guidance states that pharmacological therapy should be considered in patients with MASH and fibrosis stage F2 or greater, especially when lifestyle interventions have not produced adequate improvement over 6 to 12 months. AASLD guidance document: PubMed.

The MAESTRO-NASH investigators wrote in the NEJM 2024 publication: "Resmetirom met both primary histological endpoints, with a safety profile consistent with its hepatic selectivity, supporting its role as the first approved pharmacotherapy for MASH with fibrosis."

The Endocrine Society has also published a clinical practice guideline on thyroid disorders that contextualizes the biological basis for selective THR-β agonism as a strategy to isolate metabolic liver benefits from systemic thyroid effects. Endocrine Society thyroid guideline: PubMed.

Practical Checklist Before Starting Rezdiffra

Getting these steps completed before day one reduces the chance of treatment interruption.

• Confirm liver biopsy report showing MASH and F2 or F3 fibrosis within the past 12 months
• Review current medication list for OATP inhibitors (cyclosporine, eltrombopag) and CYP2C8 inhibitors (gemfibrozil, clopidogrel)
• Obtain baseline ALT, AST, total bilirubin, and alkaline phosphatase
• Obtain baseline lipid panel and TSH
• Confirm negative pregnancy test if applicable
• Discuss contraception plan for the duration of therapy
• Schedule week-4 follow-up appointment for dose escalation decision and lab recheck

FDA prescribing information for Rezdiffra: accessdata.fda.gov.